These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 7211191)

  • 1. Normal plasma dopamine-beta-hydroxylase in non-treated and treated Parkinson patients.
    Markianos M; Hadjikonstantinou M; Sfagos C
    Acta Neurol Scand; 1981 Apr; 63(4):267-72. PubMed ID: 7211191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma dopamine-beta-hydroxylase and erythrocyte acetylcholinesterase in a group of patients with Parkinson disease.
    Coelho H; Azevedo M; Proença C; e Silva JM; Manso C
    J Neural Transm; 1978; 42(2):163-6. PubMed ID: 650207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary homovanillic acid and c-AMP in drug-free Parkinson patients: effect of L-dopa treatment.
    Markianos M; Hadjikonstantinou M
    Eur Neurol; 1981; 20(2):118-24. PubMed ID: 6260505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum dopamine-beta-hydroxylase in parkinsonism.
    Markianos ES; Rüther E
    J Neural Transm; 1977; 40(1):21-5. PubMed ID: 833581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hereditary Parkinsonism-dystonia with sustained control by L-DOPA and anticholinergic medication.
    Allen N; Knopp W
    Adv Neurol; 1976; 14():201-13. PubMed ID: 942621
    [No Abstract]   [Full Text] [Related]  

  • 6. The neurochemistry of Parkinson's disease: effect of L-dopa therapy.
    Lloyd KG; Davidson L; Hornykiewicz O
    J Pharmacol Exp Ther; 1975 Dec; 195(3):453-64. PubMed ID: 489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma dopamine beta hydroxylase (D.B.H.) activity in Parkinsonian patients under L-dopa, and 2-bromo-alpha-ergocriptine loading.
    Vardi J; Flechter S; Oberman Z; Allelov M; Rabey JM; Hertzberg M; Streifler M
    J Neural Transm; 1979; 46(1):71-8. PubMed ID: 501350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine-beta-hydroxylase (DBH) and homovanillic acid (HVA) in autistic children.
    Garnier C; Comoy E; Barthelemy C; Leddet I; Garreau B; Muh JP; Lelord G
    J Autism Dev Disord; 1986 Mar; 16(1):23-9. PubMed ID: 3957856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary noradrenaline and serotonin metabolites in drug-free Parkinson patients and the effect of L-dopa treatment.
    Markianos M; Hadjikonstantinou M; Bistolaki E
    Acta Neurol Scand; 1982 Aug; 66(2):267-75. PubMed ID: 6182730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease: the effect of L-dopa therapy on urinary free catecholamines and metabolites.
    Davidson DF; Grosset K; Grosset D
    Ann Clin Biochem; 2007 Jul; 44(Pt 4):364-8. PubMed ID: 17594783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unresponsiveness to L-DOPA in parkinsonian patients: a study of homovanillic acid concentration in the cerebrospinal fluid.
    Nishi K; Kondo T; Narabayashi H; Takubo H; Muramoto S; Araki H
    J Neurol Sci; 1989 Aug; 92(1):65-70. PubMed ID: 2475587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dopamine beta hydroxylase. Value and limits of its study in neurology].
    Miras Portugal MT; Aunis D; Mandel P; Warter JM; Coquillat G; Collard M; Rohmer F
    Rev Neurol (Paris); 1976 Jun; 132(6):383-9. PubMed ID: 940970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Abnormal movements of patients with Parkinsonism treated with L-dopa and anomalies of dopamine metabolism].
    Lhermitte F; Rosa A; Comoy E
    Rev Neurol (Paris); 1977 Jan; 133(1):3-11. PubMed ID: 847319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease.
    Wachtel SR; Bencsics C; Kang UJ
    J Neurochem; 1997 Nov; 69(5):2055-63. PubMed ID: 9349551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma and tumor dopamine-beta-hydroxylase activity in patients with familial pheochromocytomas.
    Feldman JM; Blalock JA; Farrell RE; Wells SA
    Metabolism; 1978 Dec; 27(12):1797-802. PubMed ID: 723634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring L-dopa in plasma and urine to monitor therapy of elderly patients with Parkinson disease treated with L-dopa and a dopa decarboxylase inhibitor.
    Dutton J; Copeland LG; Playfer JR; Roberts NB
    Clin Chem; 1993 Apr; 39(4):629-34. PubMed ID: 8472357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biochemical bases of Parkinson disease].
    Colucci d'Amato C; Puccini A; Cristillo A; Vizioli R
    Recenti Prog Med; 1984 Oct; 75(10):889-901. PubMed ID: 6151219
    [No Abstract]   [Full Text] [Related]  

  • 18. [Serum dopamine-beta-hydroxylase, glutamic acid decarboxylase and 1-aromatic amino acid decarboxylase in involuntary movement disorders (author's transl)].
    Nakamura S; Miyata S; Kameyama M
    Rinsho Shinkeigaku; 1979 Aug; 19(8):511-4. PubMed ID: 159153
    [No Abstract]   [Full Text] [Related]  

  • 19. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
    J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
    Huang L; Deng M; Zhang S; Fang Y; Li L
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.